Literature DB >> 27818058

Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.

Amaury Daste1, Erwan de Mones2, Laurence Digue3, Louis François4, Charlotte Domblides3, Charles Dupin5, Antoine Bigourdan6, Alain Ravaud4.   

Abstract

Entities:  

Keywords:  Head and neck cancer; Oral cancer

Mesh：

Substances：

Year:  2016        PMID： 27818058     DOI： 10.1016/j.oraloncology.2016.10.020

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


× No keyword cloud information.
  4 in total

1.  Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.

Authors:  María Nieves Cabrera-Martín; Salomé Merino-Menéndez; Santiago Cabezas-Camarero; Mateo Paz-Cabezas; Vanesa García-Barberán; Melchor Sáiz-Pardo Sanz; Maricruz Iglesias-Moreno; Almudena Alonso-Ovies; Pedro Pérez-Segura
Journal:  Oncologist       Date:  2021-04-08

2.  Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient.

Authors:  Daiki Ogawara; Hiroshi Soda; Susumu Ikehara; Makoto Sumiyoshi; Keisuke Iwasaki; Daisuke Okuno; Yosuke Dohtsu; Hirokazu Taniguchi; Tatsuhiko Harada; Yuichi Fukuda; Hiroshi Mukae
Journal:  Thorac Cancer       Date:  2017-08-28       Impact factor: 3.500

Review 3.  Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.

Authors:  Bo Yang; Tingjun Liu; Yang Qu; Hangbo Liu; Song Guo Zheng; Bin Cheng; Jianbo Sun
Journal:  Front Oncol       Date:  2018-11-28       Impact factor: 6.244

Review 4.  PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.

Authors:  D Evrard; M Hourseau; A Couvelard; V Paradis; H Gauthier; E Raymond; C Halimi; B Barry; S Faivre
Journal:  Oncoimmunology       Date:  2020-11-19       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.